Welcome to UKTS

Sickle cell and thalassaemia screening

Screening is the process of identifying people who appear healthy but may be at increased risk of a disease or condition.

Healthcare professionals will offer information, further tests and appropriate treatment to reduce their risk or any complications arising from the disease or condition.

The NHS Sickle Cell and Thalassaemia (SCT) screening programme is a genetic screening programme. This means that it also identifies people who are genetic carriers for sickle cell, thalassaemia and other haemoglobin disorders.
Continue reading “Sickle cell and thalassaemia screening”

Parents Stories

In March 2015 the Sickle Cell and Thalassaemia Screening Programme Advisory Group set up a sub group to focus on the timeliness of antenatal screening and prenatal diagnosis. The subgroup included parents of children with sickle cell disease and thalassaemia, representatives from UKTS and the Sickle Cell Society and representatives from midwifery, obstetric and genetic counselling professional organisations.

Panel 1

Partnership with Sickle Cell Society & NHS Screening Programme

As most of you would know already, we have been working alongside the Sickle Cell Society for two major partnerships, our NHS Screening Contract and the All Party Parliamentary Group (APPG). For the Screening contract we are partnered with Ms Iyamide Thomas, a dynamic individual, who brings her years of knowledge and experience to the table.

Continue Reading

Panel 2

Latest News

Panel 3

Latest Event

The Hepatitis C Coalition is a group of leading clinicians, patient organisations and other interested parties committed to the reduction of morbidity and mortality resulting from hepatitis C, and the eventual elimination of the virus.

Some 214,000 people in the UK are thought to be living with chronic HCV. Many of these do not know that they have the virus and at present only 4% of those chronically infected receive treatment each year – an unacceptably low number.

Yet with the right diagnosis and treatment, HCV is curable, thanks to new therapies that are now available. Research from the London Joint Working Group on Substance Use & Hepatitis C (LJWG) found it was cheaper to treat chronic hepatitis C virus (CHCV) than to allow the disease to progress, and that treating just 10% of those people with HCV could save £200 million in London alone.

 

 

Panel 4

Social